Sir,

A 58-year-old male, known case of plasmablastic lymphoma, presented to our department for ^18^F-fluorodeoxyglucose positron emission tomography/computed tomography (^18^F-FDG PET/CT) for response evaluation post five cycles of chemotherapy.

Despite multiple efforts, an intravenous access could not be established because of anasarca. 15 mCi of ^18^F-FDG was diluted in 10-ml water in a disposable plastic cup, and the patient was administered the dose orally. Subsequently, the PET scan was acquired after 90 min, which showed normal physiologic distribution in the brain, kidneys, and urinary bladder along with activity visualized in the mouth and large bowel as well. Pathological uptake was noted and was compared with the previous scans \[Figure [1a](#F1){ref-type="fig"} and [b](#F1){ref-type="fig"}\]. All the previously FDG-avid sites were seen in the present scan also along with new lesions with FDG uptake, indicating progressive disease \[Figure [1c](#F1){ref-type="fig"} and [d](#F1){ref-type="fig"}\].

![(a) Maximum intensity projection of baseline ^18^F-fluorodeoxyglucose positron emission tomography/computed tomography scan (September 2018) acquired after intravenous injection. Black arrow shows the location of disease. (b) Coronal ^18^F-fluorodeoxyglucose positron emission tomography/computed tomography fused (baseline -- September 2018) showing disease involving the left humerus and left axilla. (c) Maximum intensity projection of response evaluation ^18^F-fluorodeoxyglucose positron emission tomography/computed tomography (January 2019) acquired after giving fluorodeoxyglucose orally. Red arrow shows the location of disease (progression compared to baseline scan). (d) Coronal fused ^18^F-fluorodeoxyglucose positron emission tomography/computed tomography-response evaluation showing disease progression in comparison to baseline (b)](IJNM-34-176-g001){#F1}

We reviewed literature and found a study done by Nair *et al*.,\[[@ref1]\] on two healthy volunteers and 7 patients, who underwent PET/CT after oral as well as intravenous routes of ^18^F-FDG administration. They concluded that oral ^18^F-FDG scan can successfully be substituted for intravenous ^18^F-FDG scan. A case has also been described by Franc *et al*.,\[[@ref2]\] in which a solitary pulmonary nodule was evaluated by PET/CT after oral administration of ^18^F-FDG because the patient had poor intravenous access.

Although the oral route is acceptable in assessing the lesions involving the head and neck, thorax, and peripheral sites (appendicular skeleton), it would be inappropriate to evaluate diseases of gastrointestinal (GI) tract, as majority of the administered dose persists in the GI tract. As the amount of dose absorbed through the GI tract cannot be predicted, quantitation would be unreliable and the scan needs to be acquired as late as possible as absorption from oral route would be erratic (preferable after at least 90 min).

We therefore conclude that oral administration of ^18^F-FDG is an acceptable alternative route for PET studies in patients with difficulty in establishing intravenous access with a word of caution as stated above.
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